KPC Pharmaceuticals (SHSE:600422) Net Income From Continuing Operations : ¥719 Mil (TTM As of Mar. 2025)

View and export this data going back to 2000. Start your Free Trial

What is KPC Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. KPC Pharmaceuticals's net income from continuing operations for the three months ended in Mar. 2025 was ¥114 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ¥719 Mil.

KPC Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for KPC Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KPC Pharmaceuticals Net Income From Continuing Operations Chart

KPC Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

462.18

513.21

385.46

642.67

751.22

KPC Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															145.67	88.04	156.81	360.71	113.55

KPC Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥719 Mil.

KPC Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KPC Pharmaceuticals Inc (SHSE:600422) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

No. 166 Keyi Road, State New and High-Technology Development Zone, Kunming, Yunnan, CHN, 650106

Website

http://www.kpc.com.cn

KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.

Executives

Qu Xiao Ru	senior management
Xie Bo	senior management
Meng Li	senior management
Zhong Xiang Gang	senior management
Wu Sheng Long	senior management
Liu Jun Feng	senior management
Wang Lei	senior management
Zhang Meng Xun	senior management
Hu Zhen Bo	senior management
Sun Lei	senior management
Xu Chao Neng	senior management
Wang Jun	senior management
Zhao Jian	senior management
He Qin	Director
Dai Xiao Chang	senior management

KPC Pharmaceuticals Headlines

No Headlines